Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4593654 | 0.80 | MAOA (0.40) | KDM1ASLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL4593190 | 0.69 | SLC6A3 (0.33) | SLC6A4SLC6A3SLC6A2IDO1 | |
| SCHEMBL1420518 | 0.68 | KDM1A (0.59) | KDM1ASLC6A4SLC6A3SLC6A2OPRL1 | |
| Hydrochloric Acid SCHEMBL3001569 | 0.67 | KDM1A (0.57) | KDM1ASLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL10548675 | 0.67 | KDM1A (0.45) | KDM1ASLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL28045910 | 0.67 | KDM1A (0.49) | KDM1ASLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL62723 | 0.66 | TSHR (0.67) | KDM1APNMTTSHRMAPK1TAAR1 | |
| SCHEMBL18769566 | 0.66 | SLC6A4 (0.58) | KDM1ASLC6A4SLC6A3SLC6A2KCNN4 | |
| SCHEMBL11227961 | 0.65 | TSHR (0.54) | KDM1APNMTTSHRMAPK1TAAR1 | |
| SCHEMBL7759984 | 0.65 | TSHR (0.54) | KDM1ATSHRMAPK1TAAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937257-B1 | NOVEL ANTIBIOTICS COMPRISING BIS(1-ARYL-5-TETRAZ0LYL)METHANE DERIVATIVES | TNO (NL) | 2010-12-08 | — | — | EP | claimed |
| US-20080280964-A1 | Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2008-11-13 | — | — | US | claimed |
| EP-1937257-A1 | NOVEL ANTIBIOTICS COMPRISING BIS(1-ARYL-5-TETRAZ0LYL)METHANE DERIVATIVES | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO (NL) | 2008-07-02 | — | — | EP | claimed |
| WO-2007037685-A1 | NOVEL ANTIBIOTICS COMPRISING BIS(1-ARYL-5-TETRAZ0LYL)METHANE DERIVATIVES | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2007-04-05 | — | — | WO | claimed |
| US-7964625-B2 | Antibiotics comprising bis(1-aryl-5-tetrazoly1)methane derivatives | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2011-06-21 | — | — | US | disclosed |
| EP-1937257-B1 | NOVEL ANTIBIOTICS COMPRISING BIS(1-ARYL-5-TETRAZ0LYL)METHANE DERIVATIVES | TNO (NL) | 2010-12-08 | — | — | EP | disclosed |
| US-20080280964-A1 | Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2008-11-13 | — | — | US | disclosed |
| EP-1769796-A1 | Novel antibiotics comprising bis(1-aryl-5-tetrazolyl)methane derivatives | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO (NL) | 2007-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280964-A1 | Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives | LAS1L, AAAS, RPS5 | KDM1A 1371/4885SLC6A4 3773/4885PNMT 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.